Pharmacokinetic/Pharmacodynamic antimicrobial individualization and optimization strategies

Area of Science:

• Pharmacology
• Microbiology
• Infectious Diseases

Background:

• Antimicrobial chemotherapy requires integrating pharmacology and microbiology for optimal clinical and microbiologic outcomes.
• Understanding drug-host-pathogen interactions enables rational selection of antimicrobial drug doses.
• Current clinical practices lag in adopting advances from pharmacokinetic/pharmacodynamic (PK/PD) research.

Purpose of the Study:

• To summarize decades of learning in antimicrobial chemotherapy.
• To highlight barriers preventing the translation of PK/PD research findings into clinical practice.
• To advocate for reducing these barriers to improve patient outcomes and combat antimicrobial resistance.

Main Methods:

• Review of established knowledge in antimicrobial pharmacology and microbiology.
• Analysis of existing literature on pharmacokinetic/pharmacodynamic principles.
• Identification and discussion of barriers to clinical implementation of research findings.

Main Results:

• Significant advancements have been made in understanding antimicrobial pharmacokinetics and pharmacodynamics.
• Numerous barriers hinder the effective translation of these research findings to clinical practice.
• Bridging the gap between laboratory research and bedside application remains a challenge.

Conclusions:

• Effective antimicrobial chemotherapy relies on the integration of pharmacology and microbiology.
• Translating PK/PD research into clinical practice is crucial for evidence-based medicine.
• Reducing implementation barriers can improve patient outcomes and minimize antimicrobial resistance.